Evaluation of cardiovascular risk in patients with rheumatoid arthritis: Do cardiovascular biomarkers offer added predictive ability over established clinical risk scores?

Arthritis Care and Research

Volumn 64, Issue 6, 2012, Pages 817-825

  Finckh, Axel ^a   Courvoisier, Delphine S ^b,c   Pagano, Sabrina ^a   Bas, Sylvette ^a   Chevallier Ruggeri, Paola ^a   Hochstrasser, Denis ^a   Roux Lombard, Pascale ^a   Gabay, Cem ^a   Vuilleumier, Nicolas ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN G ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIIDIOTYPIC ANTIBODY; BRAIN NATRIURETIC PEPTIDE; LOW DENSITY LIPOPROTEIN; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROGNOSIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STROKE; BLOOD; COHORT ANALYSIS; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; PREDICTIVE VALUE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; APOLIPOPROTEIN A-I; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE;

EID: 84863227338     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21631     Document Type: Article

References (50)

1. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009;61:1571-9.
2. Van Halm VP, Peters MJ, Voskuyl AE, Boers M, Lems WF, Visser M, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009;68:1395-400.
3. Del Rincon I, O'Leary DH, Freeman GL, Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis 2007;195:354-60.
4. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36-40.
5. Sodergren A, Stegmayr B, Lundberg V, Ohman ML, Wallberg-Jonsson S. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis 2007;66:263-6.
6. Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
7. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7.
8. Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009;48:1309-13.
9. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-9.
10. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-53.
11. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
12. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford) 2009;48:11-22.
13. Vuilleumier N, Bas S, Pagano S, Montecucco F, Guerne PA, Finckh A, et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2010;62:2640-50.
14. Edwards CJ, Syddall H, Goswami R, Goswami P, Dennison EM, Arden NK, et al. The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men. Heart 2007;93:1263-7.
15. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz de Rabago E, Sanchez-Ramon S, Rodriguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:419-24.
16. Vuilleumier N, Bratt J, Alizadeh R, Jogestrand T, Hafstrom I, Frostegard J. Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scand J Rheumatol 2010;39:447-53.
17. Vuilleumier N, Rossier MF, Pagano S, Python M, Charbonney E, Nkoulou R, et al. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 2010;31:815-23.
18. Montecucco F, Vuilleumier N, Pagano S, Lenglet S, Bertolotto M, Braunersreuther V, et al. Anti-Apolipoprotein A-1 autoantibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011;32:412-21.
19. Haupl T, Burmester GR, Giannitsis E, Rohrlach T, Spanuth E, Parsch H, et al. N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis? Ann Rheum Dis 2007;66:838-9.
20. Harney SM, Timperley J, Daly C, Harin A, James T, Brown MA, et al. Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis [letter]. Ann Rheum Dis 2006;65:136.
21. Peters MJ, van Halm VP, Nurmohamed MT, Damoiseaux J, Tervaert JW, Twisk JW, et al. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J Rheumatol 2008;35:1495-9.
22. Kim SH, Lee CK, Lee EY, Park SY, Cho YS, Yoo B, et al. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol Int 2004;24:230-3.
23. Ahmed HM, Youssef M, Mosaad YM. Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis. Clin Rheumatol 2010;29:1237-43.
24. Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun Rev 2002;1:233-7.
25. Vuilleumier N, Bratt J, Alizadeh R, Jogestrand T, Hafstrom I, Frostegard J. Anti-apoA-1-IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scand J Rheumatol 2010;39:447-53.
26. Srinivasan M. Ischaemic heart disease in men [letter]. Heart 2007;93:1471.
27. Sodergren A, Karp K, Boman K, Eriksson C, Lundstrom E, Smedby T, et al. Atherosclerosis in early rheumatoid arthritis: very early endothelial activation and rapid progression of intima media thickness. Arthritis Res Ther 2010;12:R158.
28. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7:R634-43.
29. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
30. D'Agostino RB. Risk prediction and finding new independent prognostic factors. J Hypertens 2006;24:643-5.
31. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.
32. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
33. Panteghini M, Clerico A. Understanding the clinical biochemistry of N-terminal pro-B-type natriuretic peptide: the prerequisite for its optimal clinical use. Clin Lab 2004;50:325-31.
34. Holvoet P. Oxidized LDL and coronary heart disease. Acta Cardiol 2004;59:479-84.
35. Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:362-70.
36. Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M. Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis 2002;61:889-94.
37. Mutru O, Laakso M, Isomaki H, Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985;290:1797-9.
38. Vuilleumier N, Charbonney E, Fontao L, Alvarez M, Turck N, Sanchez JC, et al. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci (Lond) 2008;115:25-33.
39. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
40. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum 2005;52:2293-9.
41. Kroot EJ, van Leeuwen MA, van Rijswijk MH, Prevoo ML, van't Hof MA, van de Putte LB, et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000;59:954-8.
42. Radovits BJ, Popa-Diaconu DA, Popa C, Eijsbouts A, Laan RF, van Riel PL, et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2009;68:1271-6.
43. Pereira IA, Laurindo IM, Zimmermann AF, Werner Castro GR, Mello F, Borba EF. Single measurements of C-reactive protein and disease activity scores are not predictors of carotid atherosclerosis in rheumatoid arthritis patients. Acta Reumatol Port 2009;34:58-64.
44. Tomasson G, Aspelund T, Jonsson T, Valdimarsson H, Felson DT, Gudnason V. Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis 2010;69:1649-54.
45. Heliovaara M, Aho K, Knekt P, Aromaa A, Maatela J, Reunanen A. Rheumatoid factor, chronic arthritis and mortality. Ann Rheum Dis 1995;54:811-4.
46. Kumar N, Armstrong DJ. Cardiovascular disease: the silent killer in rheumatoid arthritis. Clin Med 2008;8:384-7.
47. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-93.
48. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9.
49. Siriwardena M, Kleffmann T, Ruygrok P, Cameron VA, Yandle TG, Nicholls MG, et al. B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. Circulation 2010;122:255-64.
50. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007;115:949-52.